Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Epilepsy and Neurological Disorder Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for KCNQ3 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Stable Cell Line | KCNQ3 Stable Cell Line (Lentivirus-Derived). Full-length membrane expression maintaining native conformation. HEK293 Expressed (Native Glycosylation). Sequence Verified. Endotoxin <1EU/ug. | View KCNQ3 Products |
| Gene Delivery | KCNQ3 Premade Lentivirus Particles. Full-length ORF for stable cell line generation. High titer (>10^8 TU/ml). Sequence Verified. | View KCNQ3 Products |
| Benchmark Ab | Anti-KCNQ3 Control Antibody. Recombinant positive control for assay validation. | View KCNQ3 Products |
| Validator | KCNQ3 siRNA Set. For knockdown verification and specificity checks. | View KCNQ3 Products |
| Related Target A: KCNQ2 | KCNQ2 Lentivirus & Cell Line. Forms heteromeric M-current channels with KCNQ3. Essential for physiological relevance. | View KCNQ2 Products |
| Related Target B: KCNQ4 | KCNQ4 Cell Line. Counter-screening target to ensure subtype selectivity and avoid retigabine-like off-target effects. | View KCNQ4 Products |
| Related Target C: KCNQ5 | KCNQ5 Lentivirus & Cell Line. Homolog required for selectivity counter-screening. | View KCNQ5 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Complex Membrane Protein Conformation | High-titer Lentivirus for stable cell line generation; preserves native folding. |
| Heteromeric vs Homomeric Channel Assembly | Co-transduction Lentivirus system enabling KCNQ2/3 heteromer expression with distinct tags for pull-down validation. HEK293 background ensures correct assembly. |
| Subtype Selectivity (KCNQ2/3 vs KCNQ4/5) | Ortholog panel available: Human, Mouse, Rat KCNQ3 cell lines with >95% sequence homology verified by mass spec. KCNQ4/5 lines available for counter-screening. |
| Electrophysiological Consistency | Stable integration verified by Patch-Clamp ready membrane potential assays; Single-clone selection ensures uniform channel density (1-2 million copies/cell). |
| Lack of Reliable Controls | Sequence Verified control antibodies and expression vectors. |
| False Positives in Screening | Validated siRNA included for strict specificity checks; Non-targeting controls provided. |
Live KCNQ3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for KCNQ3 therapeutics is intensifying, with major players shifting focus from non-selective potassium channel openers (e.g., retigabine) to highly selective KCNQ2/3 heteromer activators. Following the withdrawal of retigabine due to KCNQ4/5-mediated skin and retinal pigment changes, the industry now prioritizes subtype-selective binding pockets. As early therapies (e.g., BHV-7000) reach Phase 3, the next wave of R&D is targeting state-dependent binding and CNS-optimized delivery to treat refractory epilepsy and neuropathic pain. Precise KCNQ2/3 heteromer activation while strictly avoiding off-target effects on other KCNQ isoforms is the central goal.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Activators | Xenon Pharma, Biohaven, Grunenthal, Knopp Biosciences | Epilepsy (BFNS), Neuropathic Pain, Anxiety | Selectivity Assay (Need KCNQ2/3 vs KCNQ4/5 cell lines) |
| Small Molecule Modulators | GSK, Eli Lilly | Neuropathic Pain | Electrophysiology (Need high-expression Lentivirus for functional validation) |
| Gene Therapy | Preclinical biotech | KCNQ Encephalopathy | Expression Validation (Need sequence-verified ORFs and stable cell lines) |